Global Initiative for Obstructive Lung Disease (GOLD) Criteria for COPD
ورودیهای بالینی بیمار
حداقل ۱۰ — حداکثر ۱۲۰ • واحد: % predicted
حداقل ۰.۳ — حداکثر ۱ • واحد: ratio
حداقل ۰ — حداکثر ۴۰ • واحد: points
حداقل ۰ — حداکثر ۲۰ • واحد: episodes
حداقل ۰ — حداکثر ۱۰ • واحد: admissions
پارامترهای بالینی بیمار را در فرم روبرو وارد کنید و روی «محاسبه» کلیک نمایید تا نمره، طبقه خطر و اقدامات فوری نمایش داده شوند.
- GOLD 1 - Mild COPD80–120
- GOLD 2 - Moderate COPD50–79
- GOLD 3 - Severe COPD30–49
- GOLD 4 - Very Severe COPD10–29
Clinical Decision Pathway
Clinical Decision Pathway & Next Steps
Respiratory & Pneumonia — بیماریهای تنفسی، پنومونی و COPD
Clinical Rationale:
Stratify community-acquired pneumonia with CURB-65 and PSI/PORT; monitor ROX during high-flow oxygen for intubation avoidance, and guide acute COPD exacerbation with BAP-65, DECAF, and GOLD criteria.
DECAF Score for Acute Exacerbation of COPD
امتیاز DECAF (مرگومیر بستری در COPD)
Recommended Clinical Next Steps:
BODE Index for COPD Survival
شاخص بقای BODE در COPD
Why next: Long-term multidimensional mortality prediction in COPDForward Escalation — Next Clinical Phase
The Global Initiative for Obstructive Lung Disease (GOLD) Criteria for COPD calculator is designed for bedside stratifying pneumonia severity, respiratory failure progression, and inpatient admission requirements in clinical practice. The resulting score directly guides clinician decision-making regarding determining appropriate admission level (floor versus ICU), tailoring.
Clinical Guidelines & Evidence
Clinical assessment and staging system for chronic obstructive pulmonary disease (COPD) based on spirometry, symptoms, and exacerbation risk. Provides comprehensive evaluation using FEV1 percentage predicted, symptom assessment, and treatment recommendations according to GOLD 2024-2025 guidelines.
Clinical Indication
The Global Initiative for Obstructive Lung Disease (GOLD) Criteria for COPD is indicated for bedside clinical practice to support Clinical assessment and staging system for chronic obstructive pulmonary disease (COPD) based on spirometry, symptoms, and exacerbation risk. Provides comprehensive evaluation using FEV1 percentage predicted, symptom assessment, and treatment recommendations according to GOLD 2024-2025 guidelines.. It assists healthcare providers in standardizing clinical assessment and therapeutic decision-making.
Target Population
Target population comprises Patients presenting with community-acquired pneumonia, COPD exacerbations, acute asthma, pulmonary embolism, or acute respiratory distress. Clinical application is indicated across Respiratory care units, emergency pulmonary triage, sleep clinics, and medical floors.
Limitations & Contraindications
Peripheral pulse oximetry loses reliability in hypoperfusion, severe vasoconstriction, methemoglobinemia, or carboxyhemoglobinemia.
Clinical Pearls & Action Plan
Synchronous evaluation of arterial blood gas (PaO2/FiO2), mechanics of breathing, and clinical trajectory guides respiratory failure management. Guideline pearl: Blood eosinophil count influences ICS treatment decisions.
GOLD Stage = FEV1% predicted category (1-4); COPD Group = Symptoms (mMRC/CAT) + Exacerbation risk assessment; Treatment guided by ABE assessment tool
Input Parameters
| Name | Type | Required | Description |
|---|---|---|---|
| fev1_percent_predicted | float | Yes | Forced expiratory volume in 1 second (FEV1) as percentage of predicted normal value based on post-bronchodilator spirometry(% predicted) |
| fvc_fev1_ratio | float | Yes | Post-bronchodilator FEV1/FVC ratio. Values <0.70 confirm airflow obstruction and COPD diagnosis(ratio) |
| dyspnea_mmrc | integer | Yes | Modified Medical Research Council (mMRC) Dyspnea Scale: 0=breathless only with strenuous exercise, 1=short of breath when hurrying, 2=walks slower than people of same age, 3=stops for breath after walking ~100m, 4=too breathless to leave house(grade) |
| cat_score | integer | No | COPD Assessment Test (CAT) score (0-40 points). Alternative to mMRC for symptom assessment. Scores ≥10 indicate significant symptom burden(points) |
| exacerbations_last_year | integer | Yes | Number of COPD exacerbations in the last 12 months requiring oral corticosteroids and/or antibiotics(episodes) |
| hospitalizations_last_year | integer | Yes | Number of COPD-related hospitalizations in the last 12 months due to exacerbations(admissions) |
Score Interpretation & Guidance
| Range | Stage | Description |
|---|---|---|
| 80–120 | GOLD 1 - Mild COPD | Mild airflow limitation |
| 50–79 | GOLD 2 - Moderate COPD | Moderate airflow limitation |
| 30–49 | GOLD 3 - Severe COPD | Severe airflow limitation |
| 10–29 | GOLD 4 - Very Severe COPD | Very severe airflow limitation |
Evidence-Based References (EBM)
- Global Initiative for Chronic Obstructive Lung Disease. Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease, 2025 Report. Available from: https://goldcopd.org/
- Singh SJ, Augustin IML, Correia de Sousa R, et al. An official systematic review of the European Respiratory Society/American Thoracic Society: measurement properties of field walking tests in chronic respiratory disease. Eur Respir J. 2014;44(6):1447-1478. doi: 10.1183/09031936.00150414.DOI: 10.1183/09031936.00150414
- Jones PW, Harding G, Berry P, et al. Development and first validation of the COPD Assessment Test. Eur Respir J. 2009;34(3):648-654. doi: 10.1183/09031936.00102509.DOI: 10.1183/09031936.00102509
- Bestall JC, Paul EA, Garrod R, et al. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54(7):581-586. doi: 10.1136/thx.54.7.581.DOI: 10.1136/thx.54.7.581